|
|
|
|
|
非在研适应症- |
最高研发阶段临床2期 |
首次获批国家/地区- |
首次获批日期1800-01-20 |
|
作用机制kinetoplastid proteasome抑制剂 |
在研机构- |
|
在研适应症- |
|
最高研发阶段无进展 |
首次获批国家/地区- |
首次获批日期1800-01-20 |
A Randomized, Open-label, Phase II, Single-centre Study to Evaluate the Efficacy, Safety and Pharmacokinetics of LXE408 in Patients With Primary Visceral Leishmaniasis in Ethiopia
This is a randomized, open-label, phase II, single-centre study, with one LXE408 regimen and one calibrator arm with the standard of care SSG combined with PM, to be conducted in male and female adult (≥18 years and <45 years) patients with confirmed primary visceral leishmaniasis in Ethiopia.
A phase II, multicentre, randomized, two-arm blinded study to assess theefficacy and safety of two LXE408 regimens for treatment of patients with primary visceral leishmaniasis
A Phase II, Multicentre, Randomized, Two-arm Blinded Study to Assess the Efficacy and Safety of Two LXE408 Regimens for Treatment of Patients With Primary Visceral Leishmaniasis
This is a phase II, multicentre, randomized, two-arm blinded study with an open label calibrator arm in adults and adolescents (≥12 years) with confirmed primary VL.
100 项与 kinetoplastid proteasome 相关的临床结果
100 项与 kinetoplastid proteasome 相关的转化医学
0 项与 kinetoplastid proteasome 相关的专利(医药)